Aimie Laura Peek1, Trudy Rebbeck2, Nicolaas Aj Puts3, Julia Watson4, Maria-Eliza R Aguila5, Andrew M Leaver6. 1. Faculty of Health Sciences, University of Sydney, 75 East Street, Lidcombe, NSW, 2141, Australia. Electronic address: apee6909@uni.sydney.edu.au. 2. Faculty of Health Sciences, University of Sydney, 75 East Street, Lidcombe, NSW, 2141, Australia. Electronic address: trudy.rebbeck@sydney.edu.au. 3. Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, 600 N. Wolfe Street, 21287, Baltimore, MD, USA. Electronic address: nputs1@jhmi.edu. 4. School of Clinical Sciences, Queensland University of Technology, 2 George St, Brisbane, QLD, 4000, Australia. Electronic address: julia.watson@tri.edu.au. 5. University of the Philippines, Pedro Gil Street, Ermita, Manila, 1000, Philippines. Electronic address: mraguila1@up.edu.ph. 6. Faculty of Health Sciences, University of Sydney, 75 East Street, Lidcombe, NSW, 2141, Australia. Electronic address: andrew.leaver@sydney.edu.au.
Abstract
BACKGROUND: A proposed mechanism of chronic pain is dysregulation between the main inhibitory (GABA) and excitatory (glutamate) neurometabolites of the central nervous system. The level of these neurometabolites appears to differ in individual studies of people with pain compared to pain-free controls across different pain conditions. However, this has yet to be systematically investigated. AIMS: To establish whether GABA, glutamate, glutamine and Glx levels differ across pain conditions when compared to pain-free controls. METHODS: Five databases were searched. Studies were included if they investigated: 1) A pain condition compared to control. 2) Reported GABA, glutamate, glutamine or glutamate/glutamine level. 3) Used 1H-Magnetic Resonance Spectroscopy (Prospero Project ID CRD42018092170). Data extracted included neurometabolite level, pain diagnosis, and spectroscopy parameters. Meta-analyses were conducted to establish the difference in neurometabolite level between participants with pain and pain-free controls for different pain conditions. The MRS-Q was developed from existing clinical consensus to allow for the assessment of quality in the included studies. RESULTS: Thirty-five studies were included investigating combinations of migraine (n = 11), musculoskeletal pain (n = 8), chronic pain syndromes (n = 9) and miscellaneous pain (n = 10). Higher GABA levels were found in participants with migraine compared to controls (Hedge's G 0.499, 95%CI: 0.2 to 0.798). In contrast, GABA levels in musculoskeletal pain conditions (Hedge's G -0.189, 95%CI: 0.530 to 0.153) and chronic pain syndromes (Hedge's G 0.077, 95%CI: 1.612 to 1.459) did not differ from controls. Results for other brain neurometabolites revealed significantly higher levels for glutamate in participants with migraine and Glx in chronic pain syndromes compared to controls. CONCLUSION: These results support the theory that underlying neurometabolite levels may be unique in different pain conditions and therefore representative of biomarkers for specific pain conditions.
BACKGROUND: A proposed mechanism of chronic pain is dysregulation between the main inhibitory (GABA) and excitatory (glutamate) neurometabolites of the central nervous system. The level of these neurometabolites appears to differ in individual studies of people with pain compared to pain-free controls across different pain conditions. However, this has yet to be systematically investigated. AIMS: To establish whether GABA, glutamate, glutamine and Glx levels differ across pain conditions when compared to pain-free controls. METHODS: Five databases were searched. Studies were included if they investigated: 1) A pain condition compared to control. 2) Reported GABA, glutamate, glutamine or glutamate/glutamine level. 3) Used 1H-Magnetic Resonance Spectroscopy (Prospero Project ID CRD42018092170). Data extracted included neurometabolite level, pain diagnosis, and spectroscopy parameters. Meta-analyses were conducted to establish the difference in neurometabolite level between participants with pain and pain-free controls for different pain conditions. The MRS-Q was developed from existing clinical consensus to allow for the assessment of quality in the included studies. RESULTS: Thirty-five studies were included investigating combinations of migraine (n = 11), musculoskeletal pain (n = 8), chronic pain syndromes (n = 9) and miscellaneous pain (n = 10). Higher GABA levels were found in participants with migraine compared to controls (Hedge's G 0.499, 95%CI: 0.2 to 0.798). In contrast, GABA levels in musculoskeletal pain conditions (Hedge's G -0.189, 95%CI: 0.530 to 0.153) and chronic pain syndromes (Hedge's G 0.077, 95%CI: 1.612 to 1.459) did not differ from controls. Results for other brain neurometabolites revealed significantly higher levels for glutamate in participants with migraine and Glx in chronic pain syndromes compared to controls. CONCLUSION: These results support the theory that underlying neurometabolite levels may be unique in different pain conditions and therefore representative of biomarkers for specific pain conditions.
Authors: Anna E Kirkland; Brittney D Browning; ReJoyce Green; Lorenzo Leggio; Dieter J Meyerhoff; Lindsay M Squeglia Journal: Mol Psychiatry Date: 2022-05-04 Impact factor: 15.992
Authors: Eric J Hu; Agostina Casamento-Moran; Joseph K Galaro; Kimberly L Chan; Richard A E Edden; Nicolaas A J Puts; Vikram S Chib Journal: J Neurosci Date: 2022-06-28 Impact factor: 6.709
Authors: Tamar Kolodny; Michael-Paul Schallmo; Jennifer Gerdts; Richard A E Edden; Raphael A Bernier; Scott O Murray Journal: Autism Res Date: 2020-04-16 Impact factor: 5.216
Authors: Jeungchan Lee; Ovidiu C Andronesi; Angel Torrado-Carvajal; Eva-Maria Ratai; Marco L Loggia; Akila Weerasekera; Michael P Berry; Dan-Mikael Ellingsen; Laura Isaro; Asimina Lazaridou; Myrella Paschali; Arvina Grahl; Ajay D Wasan; Robert R Edwards; Vitaly Napadow Journal: Eur J Pain Date: 2021-06-22 Impact factor: 3.651
Authors: Aimie L Peek; Andrew M Leaver; Sheryl Foster; Georg Oeltzschner; Nicolaas A Puts; Graham Galloway; Michele Sterling; Karl Ng; Kathryn Refshauge; Maria-Eliza R Aguila; Trudy Rebbeck Journal: J Pain Date: 2021-06-25 Impact factor: 5.820
Authors: Geetanjali Murari; Darren Ri-Sheng Liang; Aliya Ali; Frankie Chan; Mirjam Mulder-Heijstra; Nicolaas Paul L G Verhoeff; Nathan Herrmann; J Jean Chen; Linda Mah Journal: Cereb Cortex Commun Date: 2020-06-08
Authors: Yanez Lopez Maria; Anthony N Price; Nicolaas A J Puts; Emer J Hughes; Richard A E Edden; Grainne M McAlonan; Tomoki Arichi; Enrico De Vita Journal: Neuroimage Date: 2021-03-09 Impact factor: 6.556